What is NATROX Wound Care?
NATROX Wound Care operates at the intersection of advanced medical technology and patient-centric care. The company specializes in developing innovative solutions designed to transform the treatment landscape for chronic wounds, a condition affecting millions of individuals worldwide. By integrating sophisticated engineering with a deep commitment to medical efficacy, NATROX has established itself as a pivotal player in the wound care sector. The firm's core mission is to restore hope and improve quality of life through technology that addresses the underlying challenges of hard-to-heal wounds, supported by a corporate culture that prioritizes patient outcomes and customer commitment.
How much funding has NATROX Wound Care raised?
NATROX Wound Care has raised a total of $61.3M across 4 funding rounds:
Unspecified
$9.1M
Series A
$9.7M
Series C
$9.6M
Series C
$33M
Unspecified (2020): $9.1M with participation from Puhua Capital, Boundary Capital, Amadeus Capital Partners, and Praetura Ventures
Series A (2020): $9.7M led by Praetura Capital
Series C (2022): $9.6M supported by Wealth Club
Series C (2024): $33M featuring Meltwind, Puhua Capital, and Amadeus Capital Partners
Key Investors in NATROX Wound Care
Amadeus Capital Partners
Amadeus Capital Partners is a London-based global technology venture capital firm that invests in high-growth companies from seed to later stages across sectors such as artificial intelligence, digital health, cybersecurity, enterprise software, fintech, and deep tech.
Boundary Capital
Boundary Capital is an impact investment fund that focuses on high-growth private technology companies aimed at positively impacting millions of lives, with a specific focus on life sciences, AI, and engineering.
Puhua Capital
Puhua Capital Ltd is an early-stage growth-equity firm that provides industry resources, management experience, and investment funds to support the scaling of innovative enterprises.
What's next for NATROX Wound Care?
With the infusion of $33M, NATROX Wound Care is poised to enter a new phase of operational maturity. The strategic roadmap likely involves scaling manufacturing capabilities, expanding clinical research initiatives, and broadening its international footprint to meet the rising demand for advanced wound care solutions. As the company transitions into this enterprise-level growth stage, the focus will remain on optimizing its supply chain and strengthening its market position against competitors in the digital health and medical device sectors. Investors are closely monitoring the firm's ability to translate this capital into sustained clinical adoption and long-term value creation within the global healthcare market.
See full NATROX Wound Care company page
